BeiGene reports Q1 2025 revenue $1.1B (+49% YoY); first GAAP profitable quarter with net income $1.3M

BeOne Medicines Ltd.

2025-Q1 EPS reported $0.00 revenue$1,117,279,000

Total revenue $1.1B (+49% YoY); BRUKINSA sales $792M (+62%), now overall BTKi leader.
First GAAP profitable quarter: net income $1.3M vs loss $251M in Q1 2024; adjusted net income $136M.
Adjusted diluted EPS $1.22 vs ($1.40) prior year; operating cash flow significantly improved.
Shareholder approved renaming to BeOne Medicines and redomicile to Switzerland; investor R&D Day June 26.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.